51047-56-4

Usage

Uses

1. Used in Scientific Research:
1-(6-Pyridazinyl)piperazine is used as a research chemical for various scientific studies. Its unique structure and properties make it a valuable compound for exploring new chemical reactions and potential applications in different fields.
2. Used in Pharmaceutical Development:
1-(6-Pyridazinyl)piperazine is used as a building block in the development of new pharmaceutical compounds. Its piperazine ring system can be modified to create new drug candidates with potential therapeutic applications.
3. Used in Chemical Synthesis:
1-(6-Pyridazinyl)piperazine is used as an intermediate in the synthesis of more complex organic compounds. Its reactivity and structural features make it a useful component in the creation of new chemical entities.
4. Used in Material Science:
1-(6-Pyridazinyl)piperazine is used as a component in the development of new materials with specific properties. Its incorporation into materials can lead to the creation of novel materials with unique characteristics for various applications.

InChI:InChI=1/C8H12N4/c1-2-8(11-10-3-1)12-6-4-9-5-7-12/h1-3,9H,4-7H2

Upstream product

• 362661-27-6 1-(6'-chloro-2'-pyridazinyl)-4-benzylpiperazine 
• 492431-12-6 tert-butyl 4-(pyridazin-3-yl)piperazine-1-carboxylate 
• 56392-83-7 3-chloro-6-piperazin-1-yl-pyridazine 

Relevant academic research and scientific papers

PHENYL mTORC INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists

A series of pyridazinylpiperazines were synthesized and evaluated for VR1 antagonist activity in order to improve upon the pharmaceutical and pharmacological properties of BCTC. A structurally biased chemical library of pyridazinylpiperazine analogs was prepared in an effort to improve the pharmaceutical and pharmacological profile of the lead compound N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H) -carboxamide (BCTC). The library was evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH 5.5-induced (pH) FLIPR assays in a human VR1-expressing HEK293 cell line. The most potent VR1 antagonists were found to have IC50 values in the range of 9-200 nM with improved pharmaceutical and pharmacological profiles versus the lead BCTC. These compounds represent possible second-generation BCTC analogs.

Structure-affinity relationships of a unique nicotinic ligand: N1-dimethyl-N4-phenylpiperazinium iodide (DMPP)

DMPP is a well-known nicotinic agonist that does not fit any proposed pharmacophore for nicotinic binding and represents a unique ligand among the hundreds of nicotinic agonists studied in the past decades. A systematic modulation of the chemical structure of DMPP, aimed to establish its structure-affinity relationships, is reported. The research has allowed to identify molecules such as 11c, 13c, 14c, and 28c, with affinities for α4β2 receptors in the low nanomolar range, some 2 orders of magnitude lower than the lead compound. The agonistic properties of the most interesting compounds have been assessed by measuring their analgesic activity on mice (hot-plate test). Another result of the research was the identification of DMPP analogues, such as 3a (Ki = 90 nM) and 14b (Ki = 180 nM), that maintain affinity for the central nicotinic receptor when the ammonium function is changed into an aminic one and are therefore possible leads for drug development in neurodegenerative diseases.